IL119078A - Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them - Google Patents

Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them

Info

Publication number
IL119078A
IL119078A IL11907896A IL11907896A IL119078A IL 119078 A IL119078 A IL 119078A IL 11907896 A IL11907896 A IL 11907896A IL 11907896 A IL11907896 A IL 11907896A IL 119078 A IL119078 A IL 119078A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
substituted
compounds
substituted benzylaminopiperidine
benzylaminopiperidine compounds
Prior art date
Application number
IL11907896A
Other languages
English (en)
Other versions
IL119078A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL119078A0 publication Critical patent/IL119078A0/xx
Publication of IL119078A publication Critical patent/IL119078A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11907896A 1995-08-24 1996-08-15 Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them IL119078A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24

Publications (2)

Publication Number Publication Date
IL119078A0 IL119078A0 (en) 1996-11-14
IL119078A true IL119078A (en) 2003-11-23

Family

ID=11004362

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11907896A IL119078A (en) 1995-08-24 1996-08-15 Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them

Country Status (41)

Country Link
US (1) US6506775B1 (de)
EP (2) EP1114817B1 (de)
JP (1) JP3084069B2 (de)
KR (1) KR100288673B1 (de)
CN (1) CN1153764C (de)
AP (1) AP643A (de)
AR (1) AR006305A1 (de)
AT (2) ATE258166T1 (de)
AU (1) AU702698B2 (de)
BG (1) BG64126B1 (de)
BR (1) BR9609989A (de)
CA (1) CA2227814C (de)
CO (1) CO4480738A1 (de)
CZ (1) CZ297543B6 (de)
DE (2) DE69616817T2 (de)
DK (2) DK1114817T3 (de)
DZ (1) DZ2086A1 (de)
ES (2) ES2211684T3 (de)
HR (1) HRP960386B1 (de)
HU (1) HU225480B1 (de)
IL (1) IL119078A (de)
IS (1) IS1947B (de)
MA (1) MA23961A1 (de)
MX (1) MX9801467A (de)
MY (1) MY114800A (de)
NO (1) NO310720B1 (de)
NZ (1) NZ308207A (de)
OA (1) OA10666A (de)
PE (2) PE20010700A1 (de)
PL (1) PL186773B1 (de)
PT (2) PT1114817E (de)
RO (1) RO119299B1 (de)
RU (1) RU2152930C2 (de)
SI (2) SI1114817T1 (de)
SK (1) SK282925B6 (de)
TN (1) TNSN96107A1 (de)
TR (1) TR199800300T1 (de)
TW (1) TW340842B (de)
UA (1) UA48981C2 (de)
WO (1) WO1997008144A1 (de)
YU (1) YU49122B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
IL145945A0 (en) * 1999-05-06 2002-07-25 Pfizer Prod Inc Substituted benzolactam compounds
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
IL145949A0 (en) * 1999-05-21 2002-07-25 Pfizer Prod Inc 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
PT1095939E (pt) * 1999-10-18 2004-04-30 Pfizer Prod Inc Processo para a preparacao de eteres ciclicos de compostos com piperidinilaminometilo
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
DK1246806T3 (da) 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
MXPA03000275A (es) 2000-07-11 2004-12-13 Albany Molecular Res Inc Nuevas tetrahidroisoquinolinas substituidas con 4-fenilo y su uso terapeutico.
PA8525601A1 (es) * 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (de) * 2000-09-28 2003-03-26 Pfizer Products Inc. Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
JP2006523692A (ja) 2003-04-18 2006-10-19 イーライ リリー アンド カンパニー 5−ht1f作用薬としての(ピペリジニルオキシ)フェニル、(ピペリジニルオキシ)ピリジニル、(ピペリジニルスルファニル)フェニル、および(ピペリジニルスルファニル)ピリジニル化合物
WO2005113503A2 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US7951822B2 (en) 2008-03-31 2011-05-31 Kowa Company, Ltd. 1,3-dihydroisobenzofuran derivatives
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (de) 2009-04-01 2012-09-19 Merck Sharp & Dohme Hemmer der akt-aktivität
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
CN102595902B (zh) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
AU647592B2 (en) * 1991-03-26 1994-03-24 Pfizer Inc. Stereoselective preparation of substituted piperidines
SK282203B6 (sk) * 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (de) * 1993-11-17 1995-10-11 Pfizer Substanz P Antagonisten zur Behandlung oder Verhütung des sonnenbrandes.
EP0655246A1 (de) * 1993-11-30 1995-05-31 Pfizer Inc. Substanz P Antagonisten zur Behandlung von durch Helicobacter Pylori oder andere spirale Urease-positive Gram-negative Bakterien verursachten Krankheiten
DE69617226T2 (de) 1995-03-27 2002-07-25 Hisamitsu Pharmaceutical Co., Inc. Piperidinderivate.
PT780375E (pt) * 1995-12-21 2002-12-31 Pfizer 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
UA48981C2 (uk) 2002-09-16
NO980751D0 (no) 1998-02-23
OA10666A (en) 2002-11-25
AU5776996A (en) 1997-03-19
DE69631390D1 (de) 2004-02-26
HU225480B1 (en) 2006-12-28
ATE208377T1 (de) 2001-11-15
PT861235E (pt) 2002-03-28
KR100288673B1 (ko) 2001-05-02
TR199800300T1 (xx) 1998-06-22
SI1114817T1 (en) 2004-06-30
CO4480738A1 (es) 1997-07-09
AP9600850A0 (en) 1996-10-31
DK0861235T3 (da) 2001-12-27
CZ297543B6 (cs) 2007-02-07
EP1114817A1 (de) 2001-07-11
YU47896A (sh) 1998-12-23
EP0861235A1 (de) 1998-09-02
SI0861235T1 (en) 2002-04-30
RO119299B1 (ro) 2004-07-30
NO980751L (no) 1998-02-23
BG64126B1 (bg) 2004-01-30
IL119078A0 (en) 1996-11-14
SK20798A3 (en) 1999-03-12
MY114800A (en) 2003-01-31
PT1114817E (pt) 2004-05-31
MA23961A1 (fr) 1997-04-01
DK1114817T3 (da) 2004-04-26
SK282925B6 (sk) 2003-01-09
AP643A (en) 1998-04-24
DE69616817D1 (de) 2001-12-13
MX9801467A (es) 1998-05-31
HUP9901159A2 (hu) 1999-07-28
JPH10510554A (ja) 1998-10-13
JP3084069B2 (ja) 2000-09-04
YU49122B (sh) 2004-03-12
TNSN96107A1 (fr) 2005-03-15
ATE258166T1 (de) 2004-02-15
IS1947B (is) 2004-10-13
HUP9901159A3 (en) 2000-05-29
KR19990044077A (ko) 1999-06-25
PL186773B1 (pl) 2004-02-27
DE69616817T2 (de) 2002-04-04
EP1114817B1 (de) 2004-01-21
EP0861235B1 (de) 2001-11-07
DZ2086A1 (fr) 2002-07-22
NZ308207A (en) 1998-07-28
CZ52198A3 (cs) 1999-01-13
WO1997008144A1 (en) 1997-03-06
IS4644A (is) 1997-12-30
PE1398A1 (es) 1998-02-27
AU702698B2 (en) 1999-03-04
NO310720B1 (no) 2001-08-20
RU2152930C2 (ru) 2000-07-20
AR006305A1 (es) 1999-08-25
BR9609989A (pt) 1999-07-06
PL325332A1 (en) 1998-07-20
CA2227814A1 (en) 1997-03-06
BG102288A (en) 1998-09-30
CN1153764C (zh) 2004-06-16
US6506775B1 (en) 2003-01-14
HRP960386A2 (en) 1998-04-30
CN1193961A (zh) 1998-09-23
HRP960386B1 (en) 2002-04-30
DE69631390T2 (de) 2004-11-25
ES2163017T3 (es) 2002-01-16
ES2211684T3 (es) 2004-07-16
TW340842B (en) 1998-09-21
HK1014935A1 (en) 1999-10-08
CA2227814C (en) 2002-12-31
PE20010700A1 (es) 2001-07-09

Similar Documents

Publication Publication Date Title
HU9601698D0 (en) Pharmaceutical composition
IL116851A (en) 3-arylidene-2-oxindole derivatives and pharmaceutical compositions containing them
IL122618A0 (en) Substituted imidazolylacetonitrile compounds their preparation and pharmaceutical compositions containing them
AP9701160A0 (en) Compounds and pharmaceutical compositions containing them
ZA967827B (en) Pharmaceutical compositions
HUP9901452A3 (en) Bicyclic-aromatic compounds and pharmaceutical compositions containing them
ZA962214B (en) Pharmaceutical composition
ZA967800B (en) Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
GB9519667D0 (en) Pharmaceutical composition
EG24294A (en) Pharmaceutical compositions
IL117397A (en) Substituted naphthyl compounds and pharmaceutical compositions comprising them
ZA963590B (en) Pharmaceutical composition
GB9506382D0 (en) Pharmaceutical compositions
GB9513972D0 (en) Pharmaceutical compositions
GB9525194D0 (en) Pharmaceutical composition
ZA961051B (en) Pharmaceutical composition
ZA964193B (en) Pharmaceutical composition
HUP9802291A3 (en) Penicillaminamide derivatives and pharmaceutical compositions containing them
HU9602822D0 (en) Pharmaceutical composition
HUP9802072A3 (en) Benzothiopyranoindazole derivatives and pharmaceutical compositions containing them
HUP9602732A3 (en) Pharmaceutical composition comprising lanperisone
ZA95736B (en) Pharmaceutical composition
GB9506301D0 (en) Pharmaceutical compositions
GB9511480D0 (en) Pharmaceutical compositions
GB9517133D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees